MAS
WST icon

Meeder Advisory Services’s West Pharmaceutical WST Stock Holding History

Meeder Advisory Services’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$412K Buy
1,147
+56
+5% +$17.1K 0.02% 476
2026
Q1 		$274K Sell
1,091
-239
-18% -$59.5K 0.01% 549
2025
Q4 		$366K Sell
1,330
-458
-26% -$125K 0.02% 462
2025
Q3 		$469K Buy
1,788
+242
+16% +$58.8K 0.02% 403
2025
Q2 		$338K Sell
1,546
-505
-25% -$108K 0.02% 461
2025
Q1 		$459K Buy
2,051
+400
+24% +$110K 0.03% 372
2024
Q4 		$541K Buy
1,651
+280
+20% +$88.1K 0.03% 334
2024
Q3 		$412K Sell
1,371
-53
-4% -$16.2K 0.03% 382
2024
Q2 		$469K Buy
1,424
+270
+23% +$95.4K 0.03% 326
2024
Q1 		$457K Buy
1,154
+7
+0.6% +$2.59K 0.05% 291
2023
Q4 		$404K Sell
1,147
-24
-2% -$8.49K 0.05% 295
2023
Q3 		$439K Sell
1,171
-274
-19% -$106K 0.06% 283
2023
Q2 		$553K Buy
1,445
+108
+8% +$38.6K 0.06% 267
2023
Q1 		$463K Buy
+1,337
New +$391K 0.05% 290

Other funds holding WST

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $10.3B AUM 4.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Meeder Advisory Services's WST Position: Q2 2026 in Review

Meeder Advisory Services increased its West Pharmaceutical (WST) stake by 5.1% in Q2 2026, buying an estimated $17.1K and bringing the position to 1,147 shares worth $412K. The position accounts for 0.02% of the portfolio, ranked #476.

Meeder Advisory Services first reported a position in WST in Q1 2023 and has held it in 14 quarters since. The position peaked at $553K in Q2 2023. 834 funds tracked by Wall St. Rank hold WST as of Q2 2026.

  • Meeder Advisory Services held 1,147 shares of West Pharmaceutical worth $412K as of Q2 2026.
  • Meeder Advisory Services bought 56 West Pharmaceutical shares in Q2 2026, an estimated $17.1K.
  • West Pharmaceutical made up 0.02% of Meeder Advisory Services's portfolio in Q2 2026, its #476 holding.
  • Meeder Advisory Services first reported a position in West Pharmaceutical in Q1 2023 and has held it in 14 quarters since.
  • Meeder Advisory Services's West Pharmaceutical position peaked at $553K in Q2 2023.
  • 834 funds tracked by Wall St. Rank held West Pharmaceutical as of Q2 2026.

Based on Meeder Advisory Services's 13F filing for Q2 2026, filed 7 Aug 2026.